Contemporary approaches to bifurcation stenting

Claire E Raphael¹ and Peter D O’Kane²

Abstract
Bifurcation lesions are common and associated with higher risks of major cardiac events and restenosis after percutaneous coronary intervention (PCI). Treatment requires understanding of lesion characteristics, stent design and therapeutic options. We review the evidence for provisional vs 2-stent techniques. We conclude that provisional stenting is suitable for most bifurcation lesions. We detail situations where a 2-stent technique should be considered and the steps for performing each of the 2-step techniques. We review the importance of lesion preparation, intracoronary imaging, proximal optimization (POT) and kissing balloon inflation.

Keywords
Bifurcation, PCI, culotte, DK crush

Introduction
Bifurcation lesions constitute up to 20% of lesions treated with percutaneous coronary intervention (PCI).¹ Blood flow dynamics at branch vessels result in differing shear stress, increasing the likelihood of atherosclerosis. Severe lesions commonly occur in these sites but the carina or flow-divider is usually spared from plaque formation because of relatively high blood flow. The anatomy also makes PCI more challenging² and rates of major adverse cardiac events (MACE) following PCI are much higher compared to non-bifurcation lesions.

Methods
Literature review was performed using PUBMED and the key words “coronary” and “bifurcation”, review of consensus documents and opinions of thought leaders in the field.

Definition of bifurcations and anatomic considerations
The most common classification system for bifurcation lesions is the Medina classification³ (Figure 1). This is a 3-digit binary code which defines a bifurcation by the presence of disease proximal and distal to the bifurcation in the main vessel (MV) and presence/absence of disease in the side branch (SB). This system has proved popular due to its simplicity, however it does not provide insight on plaque morphology, extent of disease nor angulation, which are all key informatics when strategizing PCI therapeutic options. The Medina classification does not take into consideration the size of the side branch, although modifications to address this have been suggested.⁴ Alternative classifications have been proposed that allow division of bifurcation lesions into simple and complex, using factors such as the relative angulation of the vessels, degree of calcification and lesion length (Figure 2). These criteria have been shown to predict outcomes following PCI and may help decision making between a provisional stent (PS, 1 stent) and 2-stent strategy.⁵,⁶

¹Mayo Clinic, Rochester, MN, USA
²Royal Bournemouth Hospital, Dorset, UK

Corresponding author:
Claire E Raphael, Division of Cardiology, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA.
Email: claire.raphael@gmail.com
Specific anatomic considerations in bifurcation lesions

A fundamental physical principle of bifurcation PCI is that a main vessel (MV) coronary artery diameter always diminishes after a major side branch (SB). The size of MV and SB after a bifurcation is determined by the size of the proximal MV and may be approximated as follows:

$$\text{Proximal MV diameter} = \frac{2}{3} (\text{distal MV diameter} + \text{SB diameter})$$

Figure 1. The Medina classification is based on anatomic lesions, giving each bifurcation a 3 digit binary code. If there is a lesion >50%, it is classified as “1” and if <50% it is a “0”. The first figure represents the proximal main vessel, the second, the distal main vessel and the third the side branch. Each classification is demonstrated in the figure. Reproduced from Ali et al. 2

Figure 2. The DEFINITION study grouped bifurcation lesions into “complex” and “simple” lesions using criteria that predicted major adverse events post PCI. A complex lesion is defined as meeting the criteria in the first box and with at least two of the characteristics listed in the second box (adapted from Melikian et al. 3).

**DEFINITION study: Complex bifurcation lesions**

- Any two of:
  - Moderate to severe calcification
  - Multiple lesions
  - Active thrombus
  - Bifurcation angle <45°
  - MB reference diameter <2.5mm
  - MB lesion >25mm length

Specific anatomic considerations in bifurcation lesions

A fundamental physical principle of bifurcation PCI is that a main vessel (MV) coronary artery diameter always diminishes after a major side branch (SB). The size of MV and SB after a bifurcation is determined by the size of the proximal MV and may be approximated as follows:

$$\text{Proximal MV diameter} = \frac{2}{3} (\text{distal MV diameter} + \text{SB diameter})$$
After adequate lesion preparation, the stent selected should therefore be sized to the distal MV reference diameter, either using angiographic images or adjunctive intra-coronary imaging (intravascular ultrasound, IVUS/optical coherence tomography, OCT). Oversizing of the stent diameter risks carina shift and closure of the SB. Following implantation, as the stent is a uniform diameter throughout its length, the segment proximal to the carina will be unapposed. The next step is therefore to use a larger diameter proximal balloon to expand the stent, the ‘proximal optimization technique’ (POT). This is essential in all bifurcation stenting strategies and is often applied multiple times during the PCI. Registry data supports better outcome in patients treated with POT (TLF 4% vs 6% for no POT, p < 0.01), ST (0.4% vs 1.3% with no POT, p < 0.01).8 The POT balloon must not extend beyond the carina to avoid over-expansion of the distal MV and closure of the SB through carina shift. Perfectly aligned POT balloon inflation affords stent strut opening into the SB whilst fully apposing the stent to the walls of the proximal vessel (Figure 3). Ensuring adequate stent length proximal to the carina is also essential to avoid geographical miss i.e. balloon injury outside of stent.

Stent expansion limits are fixed depending on stent design (open vs closed cells, number of cross linkages, crown number) and diameter, it is important to select a device that can be expanded to the MV diameter without deformation of the stent architecture. This is particularly pertinent when there is a large size differential between the proximal and distal vessel. The maximal expansion diameters of common stents may be found in the product IFU and selected publications.9

Choosing a strategy for bifurcation treatment

When deciding how to treat a bifurcation lesion, the first consideration is usually between an upfront PS or two stent strategy. The choice of approach for treatment of bifurcations depends on the lesion characteristics and complexity.5 The current European Bifurcation Club (EBC) guidelines10 suggest that PS may be the preferred option for most lesions, while an upfront 2-stent strategy may be considered for more complex lesions with a large side branch supplying a significant myocardial territory. However, the PS approach is in reality a philosophy that when followed, permits predictable results in both MV and SB. While in most situations a stent is implanted only in MV, additional SB stents can be deployed if necessary.

Lesion preparation and use of intra-coronary imaging

The lesion must be adequately prepared to ensure full stent expansion. There should be a low threshold for intracoronary imaging as this will guide lesion preparation and size of stent(s). Cutting and scoring balloons are helpful for fibrotic and mild/moderately calcified lesions, while severely calcified lesions may require rotablation. More recently, intravascular lithoplasty using the Shockwave balloon (Shockwave Medical, Santa Clara) has emerged as a promising treatment for circumferential calcification.11

During bifurcation stenting, OCT allows identification of whether wire cross is through a proximal or distal strut12 (Figure 4). Following stent implantation, IVUS and OCT may be used to ensure optimal stent expansion. OCT to guide bifurcation stenting will be assessed in the European Randomized Optical Coherence Tomography Optimized Bifurcation Event Reduction Trial (OCTOBER) trial.13

Provisional stent technique

The steps for PS are shown in Figure 5. Decision to wire the SB will depend on patient stability, the area of viable myocardium supplied by the SB (which may be estimated by visual assessment of the diameter and length of the SB), the likelihood of loss of flow following PS (based on degree and morphology of disease in the ostial/proximal SB) and how difficult it would be to wire the SB in the event of compromised flow. In practice, the SB is usually wired. Routine SB pre-dilatation is not recommended but may be considered if SB access is difficult or there is severe SB disease in the ostial/proximal vessel.10

Following PS, POT is performed, usually with the SB wire jailed behind the MV stent. Jailing the SB wire may help the SB to remain open and will provide a marker for position if flow is lost. For small SBs, once the MB is stented and POT is performed, if there is normal flow in the SB, there is no need to treat the SB as this may risk ostial SB dissection. If flow is lost, the SB is rewired after POT, either with a new wire or by bringing the MV wire back (avoiding unintentional abluminal wiring if the POT is suboptimal) and gentle SB dilatation performed. Wire crossing through a distal MV stent strut is optimal to permit better scaffolding of the SB ostium during FKB and to avoid MV proximal stent deformation. This should be followed by repeat POT. For larger SBs, both SB and MV should be wired and following MV stenting and POT, wire re-cross into the SB and kissing balloon inflation (KBI) (see Figure 3). If KBI is performed, a final POT is necessary.
Figure 3. Importance of proximal optimization technique (POT). The POT balloon is sized 1:1 to the proximal MV. If the balloon is too proximal, there will be incomplete expansion of stent at ostial SB and a risk of proximal edge dissection/geographical miss. A too distal POT will deform the stent causing carina shift and reduction in the size of the ostial SB. The distal MV may be traumatized by the oversized balloon. There is also a risk of missing the proximal aspect of the stent which would then be under-expanded and unopposed to the vessel wall. Figure adapted from EBC.\textsuperscript{10}
to restore circular geometry and reduce strut malapposition in the MV. The final POT should have a more proximal balloon position especially if the SB has been stented so as to avoid any neocarina that will have been created.

A second stent in the SB using either T, T and protrusion (TAP) or culotte as a bail-out 2 stent strategy may be needed in the following circumstances (1) compromised SB flow, (2) SB dissection that may compromise flow (3) severe stenosis. However, ensuring an optimal result in the MB should be prioritized over optimizing the SB.

**Figure 4.** OCT may be used to guide recrossing during bifurcation PCI. Here, a fly through image shows a proximal cell recross into the circumflex in a distal left main bifurcation.

**Figure 5.** Provisional stent approach. A single stent is placed across the bifurcation. The proximal stent is optimised (POT) with a non compliant balloon sized to the proximal main vessel size. Rewiring of the side branch and kissing balloon inflation are commonly performed to optimize the ostium of the side branch but are not mandatory.
Table 1. Key trials in non-LMS bifurcation stenting.

| Trial                        | n     | Comparator arm 1 | Comparator arm 2 | Primary endpoint                                         | Results                                                                                                                                 |
|------------------------------|-------|------------------|------------------|----------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|
| NORDIC Bifurcation Study I 2006\(^8\) | 413   | PS               | 2 stent (classic crush, T-stenting, culotte) | MACE (death, MI, TVR, ST) at 6 months | Similar MACE between groups. Longer procedure time and higher rates of raised biomarkers post procedure in 2-stent group |
| DK crush I 2008\(^5\)        | 311   | Classic crush    | DK crush         | MACE (cardiac death, MI, TVR) at 8 months               | DK crush associated with lower rates of MACE at 8 months compared to classic crush (11.4% vs 24.4%, p = 0.002). FKBI achieved in 100% of patients treated with DK crush compared to 76% in the classic crush group |
| BBK I 2008\(^9\)            | 101   | T stent          | PS + KBI with bailout T stent if SB compromise | % stenosis of the SB at 9 month angiographic follow up | No difference in SB stenosis between groups |
| CACTUS 2009\(^10\)          | 350   | PS with bailout T stent | Classic crush    | 6 month angiographic restudy | Difference in re-stenosis between the two groups in either the MV or SB. Rates of major adverse events (cardiac death, MI, TLR) at 6 months similar between groups |
| BBC ONE 2010\(^2\)          | 500   | PS with optional FKB | 2-stent (crush, T, culotte) with mandatory FKB | MACE (death, MI, TVF) | Higher rates of MACE in 2-stent compared to PS (8% vs 15%, p = 0.009), largely driven by periprocedural MI. 2-stent procedures had longer duration and fluroscopy time |
| DK crush 2 2011\(^2\)       | 370   | DK crush         | PS               | MACE (cardiac death, MI, TVR) | No difference in MACE between groups. DK crush associated with a significant reduction of TLR and TVR. |
| Nordic Baltic III 2011\(^2\) | 477   | PS + FKB         | PS without FKB   | MACE (death, MI, TVF) | No difference in MACE. Lower rates of SB stenosis in the FKB group (7.9% vs 15.4%, p = 0.039) on 8month angiographic study |
| BBC I/Nordic Bifurcation 5 year follow up\(^2\) | 890   | PS               | 2 stent (classic crush, T-stenting, culotte) | All cause mortality at 5 years | Lower mortality with PS vs 2 stent (3.8% vs 7.0%, p = 0.04) |
| DK crush 6 2015\(^24\)      | 320   | PS approach. Decision to stent SB guided by FFR | PS approach. Decision to stent SB made angiographically | 1 year composite MACE (cardiac death, MI and clinically driven TLR) | No difference in MACE between groups. Numerically lower % of SB stent in FFR group (56% vs 63%, p = 0.07) |
| Nordic II 2009\(^2\)        | 424   | Culotte          | Classic Crush    |                                                        | (continued)                                                                   |
| Trial                          | n  | Comparator arm 1 | Comparator arm 2 | Primary endpoint                                             | Results                                                                 |
|-------------------------------|----|------------------|------------------|-------------------------------------------------------------|-------------------------------------------------------------------------|
| EBC TWO 2016                  | 200| PS               | Culotte          | MACE (cardiac death, MI, TVR or ST) at 6 months             | No difference in MACE between groups (crush 4.3%, culotte 3.7%, \( p = 0.87 \)). |
| BBK II 2016                   | 300| Culotte          | TAP              | MACE (death, MI, TVR) at 12 months.                         | No difference in MACE (7.7% in T stent vs 10.3% in culotte, \( p = 0.53 \)). |
| PERFECT 2015 - first randomization | 306| FKB             | no FKB           | Angiographic assessment at 8 months.                        | Angiographic restenosis was higher in the MV in FKB group compared to no FKB (15.1% vs 3.7%, \( p = 0.004 \)). No difference in the SB (2.8% vs 5.6%, \( p = 0.5 \)). No difference in MACE (14.0% versus 11.6%, \( p = 0.57 \)). |
| PERFECT 2015 - second randomization | 419| PS               | Mini crush       | as above                                                    | No difference in angiographic restenosis between groups in the SB or MV. MACE similar between groups at 1 year (17.9 vs 18.5%, \( p = 0.84 \)). |
| CELTIC (2018)                 | 170| Culotte with Xience (3 connector design) | Culotte with Synergy stent (2 connector design) | MACE:death, MI, CVA and TVR.                               | Synergy non-inferior to Xience (9 month MACE 1% for Xience and 16% for Synergy) |
| DEFINITION II (2020)          | 653| PS, complex bifurcation lesions (DEFINITIONS criteria) | 2 stent (77% DK crush). Complex bifurcation lesions (DEFINITIONS criteria) | TLF at 1 year (cardiac death, target vessel MI, clinically driven TLR) | Favored 2 stent technique for complex bifurcation lesions; TLF occurred in 37 (11.4%) in the PS and 20 (6.1%) patients in the 2-stent group, respectively, HR 0.52, 95% CI 0.30–0.90; \( p = 0.019 \), largely driven by target vessel MI and clinically driven TLR in the PS group |

PS – provisional stent, POT – proximal optimization technique, MI – myocardial infarction, TVR – target vessel revascularization, ST – stent thrombosis, DK – double kiss, MACE – major adverse cardiac events, FKB1 – final kissing balloon inflation, SB – side branch, TLR – target lesion revascularisation, MV – main vessel, LMS – left mainstem, FFR – fractional flow reserve, TIMI – thrombolysis in myocardial infarction, TLF – target lesion failure, TAP – T stent and protrude.
Two-stent techniques

The sequence for the most common 2-stent techniques are in Figures 6 to 8 and the pros and cons of each technique summarized in Table 1. In the culotte and reverse culotte, the distal MV and SB each contain a “trouser leg” of stent, with 2 layers of stent in the proximal MV (Figure 6). In the traditional culotte, the SB stent is placed first, while the MV is stented first in the reverse culotte. Culotte was traditionally limited by large differences in MV and SB diameter but contemporary stent expansion flexibility permits up to 1.5 mm difference. T stenting and TAP (T-stent and protrusion) is best suited to lesions where the SB is close to 90° to the MV (Figure 7). Double kiss crush (DK crush) has multiple steps and wire re-crosses (Figure 8). It is a modification of the classic crush technique with the addition of a re-cross and KBI after deployment of the SB stent, increasing the success of wire re-cross for the final KBI from 75% to close to 100%. A successful final KBI is associated with a reduction in major adverse events.15 DK crush is usually reserved for distal left main stem bifurcations where angulation is 90° or more. Trial data performed by high volume DK crush operators suggests superiority over other bifurcation techniques,16,17 however may not be generalizable to lower volume centres/operators. Whichever 2-stent technique is applied, it is mandated that FKB is performed with subsequent POT.

Trial data

The major trials of bifurcation stenting are summarized in Table 1, with details of left mainstem (LMS) trials in Table 2. The majority of trials were performed in the
First generation drug eluting stent (DES) era with thicker stent struts, durable polymer and paclitaxel in a high proportion. 2-stent techniques were also much less refined with absence of the POT concept, single kiss crush and low use of intra-coronary imaging. Perhaps not unsurprisingly the trial data largely supports the use of a PS strategy over an upfront 2-stent strategy. Importantly, many of these trials included small SB diameters. Pros and cons of each of the 2 stent techniques are detailed in Table 3.

**Left main stem bifurcation lesions**

The EXCEL²⁸ and NOBLE²⁹ trials suggested that PCI for unprotected LMS disease resulted in similar rates of cardiovascular mortality to bypass surgery but a higher risk of requirement for repeat revascularization and higher all cause mortality at 5 years.³¹ This 5-year outcome data for EXCEL generated a large amount of controversy and led to the European Association for Cardio-Thoracic Surgery (EACTS) withdrawing their support for the ESC IIa recommendation for LMS PCI in low and intermediate syntax scores.³² In a post hoc analysis of EXCEL, patients with a Syntax II score that favored CABG but who were treated with PCI had higher mortality compared with those randomized to CABG (15.1% vs 4.1%, \( P = 0.02 \)).³³ The decision for PCI vs CABG in LMS disease should utilize a heart team approach, assessing anatomic complexity and relative risks/benefits of each approach.

If PCI is utilized for LMS revascularization, the results of DK crush III and V suggest that DK crush may be the preferred technique for true bifurcations and this has a class IIb recommendation in the most recent ESC guidelines.³⁴ However, the DK crush trials were performed by operators who performed >300 PCIs/year, including at least 20 LMS PCIs per year, raising the question of whether outcomes would be similar in lower volume operators. DK crush has not been similarly endorsed in the EBC¹⁰ or AHA/ACC guidelines. Subgroup analysis of distal LMS bifurcation lesions in EXCEL demonstrated a higher rate of composite end point (death, MI, stroke) at 3 years in patients treated with a planned 2-stent technique.

**Figure 7.** T stent/TAP, treating MV first. The first 4 steps of this procedure are the same as provisional stenting so this can be used as a bailout technique if there is a large dissection in the SB or compromise of SB flow, converting the provisional strategy to a T stent/TAP strategy.
compared to PS (20.7% vs 14.1%, \( p = 0.01 \)), driven by differences in cardiovascular and MI.\textsuperscript{35} The results of the EBC MAIN trial which randomizes patients to a 2-stent vs PS strategy for LMS bifurcation stenting are awaited and will help inform the PS vs 2 stent decision.

**Dedicated bifurcation stent platforms**

Whilst data supports a PS approach only whilst preserving flow in the SB, technically this can be difficult and it is often necessary to first secure the SB to prevent occlusion. Furthermore, when the SB is a large calibre vessel supplying extensive myocardial territory it may be necessary to provide a durable result in this vessel to improve angina independent of the MV. Anatomical variation of angulation and presence of fibro-calcific disease in these cases adds additional complexity and desire to use the most simple and effective strategy is paramount.

The concept of using a dedicated bifurcation stent that could overcome some of the limitations of using standard stents to treat complex bifurcation lesions has been extensively explored. A number of devices have been developed that at first appeared promising but ultimately failed to prove superior to conventional techniques in clinical practice. Very few now exist in clinical use, which largely reflects a lack of evidence to support superiority of current bifurcation PCI techniques and that some were technically challenging to implant.

Devices can be divided into stents which cover the proximal aspect of the bifurcation lesion (e.g. Axxess), stents designed to cover the proximal and distal MV with SB access (e.g. Stentys coronary bifurcation stent) and side branch stents designed to be delivered in the proximal MV into the SB (e.g. Tryton).

---

**Figure 8.** DK crush technique. This is the most complex of the bifurcation techniques. It has the advantage of maintaining wire access in the MV throughout. Two KBI (unlike classic or mini-crush) are performed which increases the success of re-cross after MV stenting.
### Table 2. Key trials in LMS bifurcation stenting (abbreviations as per Table 1).

| Trial         | n   | Patient population                     | Comparator arm 1 | Comparator arm 2 | Primary endpoint                                      | Results                                                                 |
|---------------|-----|----------------------------------------|------------------|------------------|------------------------------------------------------|-------------------------------------------------------------------------|
| DK crush 3    | 419 | Unprotected distal LM bifurcation lesions (Medina 1,1,1 or 0,1,1) | DK crush         | Culotte          | MACE (cardiac death, MI and TVR)                    | Higher rates of MACE following culotte vs DK crush (16.3% vs 6.2%, p < 0.05), mainly driven by increased TVR (11% vs 4.3%, p < 0.05) |
| (2013)\(^{13}\) |     |                                        |                  |                  |                                                      |                                                                         |
| EXCEL (2016)\(^{28}\) | 1905 | Unprotected LMS disease of low/intermediate complexity (Syntax score 32 or less) | PCI              | CABG             | composite of death from any cause, stroke, or MI at 3 years | Primary endpoint in 15.4% of PCI group vs 14.7% of CABG group (P = 0.02 for noninferiority, p = 0.98 for superiority). Secondary end-point of death, stroke, MI at 30 days occurred in 4.9% of PCI group vs 7.9% of CABG group (P < 0.001 for noninferiority, p = 0.008 for superiority). MACCE at 5 years: 28% for PCI (121 events) vs 18% for CABG (80 events). HR 1.51 (95% CI 1.1-2.0). CABG was statistically superior to PCI (p = 0.004). Lower rates of TLF with DK crush vs PS (10.7% vs 5.0%, p = 0.02) |
| NOBLE (2016)\(^{29}\) | 598  | Unprotected LMS disease                  | PCI              | CABG             | MACCE at 5 years: composite of all-cause mortality, non-procedural MI, any repeat coronary revascularisation, stroke |                                                                         |
| DK crush 5    | 482  | Unprotected distal LM bifurcation lesions (Medina 1,1,1 or 0,1,1) | PS               | DK crush         | Composite of TLF: cardiac death, target vessel MI, or clinically driven TLR at 1 year | Lower rates of TLF with DK crush vs PS (10.7% vs 5.0%, p = 0.02)          |
| (2017)\(^{10}\) |     |                                        |                  |                  |                                                      |                                                                         |

### Table 3. Pros and cons of 2 stent techniques.

| 2 stent technique | Pros                                                                 | Cons                                                                                           |
|-------------------|----------------------------------------------------------------------|------------------------------------------------------------------------------------------------|
| PS                | • Most simple technique                                            | • Associated with higher rates of MACE in DEFINITIONS II (complex bifurcations) and DK crush V (udLMS) |
|                   | • Can be converted to T stent/TAP/culotte as bail out              |                                                                                                 |
|                   | • Data supports PS for most bifurcation lesions, except complex and LMS |                                                                                                 |
| DK crush          | • Data for superiority over PS and culotte in LMS                 | • Complex with multiple steps                                                                   |
|                   | • Maintains wire access in MV                                      | • Results may not be replicated in low volume centres/operators                                  |
|                   |                                                                 | • Greater fluroscopy and contrast dye.                                                        |
|                   |                                                                 | • Can be difficult to perform through 6 F system (7 F often preferred)                         |
| T stent/          | • Best in bifurcations where SB is at 90°                          | • May result in geographic miss of ostial SB                                                  |
| TAP Culotte       | • Best in bifurcation angles < 70° and where SB is of similar size to distal MV. | • 2 layers of stent in proximal MB                                                            |
|                   |                                                                 | • Multiple steps of re-wiring                                                                |
The Axxess™ stent was a conical self-expanding nitinol stent that was coated with Biolimus with a bio-absorbable polymer. The device was designed to adopt a provisional approach with delivery in the MV across the carina permitting easy access to both SB and distal MV to allow additional DES overlap as required. When placed in an optimal position, the acute results and out to 5 years were excellent in over 125 implants in our centre and in some small published registries. However, the learning curve for use, necessity to have very extensive lesion preparation and relatively high cost resulted in the withdrawal of Axxess from the market a few years ago.

The Stentys™ coronary bifurcation stent (Stentys, SAS, Paris, France) is a self-expanding, drug-eluting stent. The stent is composed of Z shaped cells in a mesh that can be folded into the ostium of the side branch using an angioplasty balloon. It is positioned in the MV across the SB and deployed by withdrawal of the covering sheath. The stent will then self expand and conform to the main vessel. The guidewire is then repositioned into the SB and a non-compliant balloon inflated in SB ostium causes some of the stent struts to disconnect, resulting in full expansion of the stent into the bifurcation. A workhorse drug eluting (or other) stent may be placed in the SB if desired.

The BiOSS (Bifurcation Optimization Stent System, Balton, Warsaw, Poland) is a stainless steel dedicated bifurcation stent, designed with a tapered shape to fit with the size differential of the main vessel between the proximal and distal segments, with a ratio of 1.3–1.15 of proximal: distal stent. It is inflated through a bottle shaped balloon, designed for an immediate “POT effect” on implantation. The POLBOS II trial (PMID 26600564) demonstrated non inferiority to provisional stenting with workhorse drug eluting stents.

The Tryton Bifurcation stent (TBS) is a slotted tube stent with three zones designed to be used in conjunction with a 2nd generation drug eluting stent when treating a bifurcation lesion using a culotte technique. The device was very simple to use adopting a modified Culotte strategy with treatment first to SB after lesion preparation. Due the tri-zone design, re-crossing from the SB to MV with the guide wire through the transition zone was easy and reproducible permitting completion of the culotte with DES to MV and effectively avoiding the double layer of proximal MV stent found in conventional DES culotte technique. Despite the cobalt-chromium device being free of drug, the TLR from many registries was relatively low and similar in my experience of over 75 cases (including 5 in a LM registry). However, it proved no better in terms of MACE against provisional approach in the major RCT of 700 patients and is now no longer available in the UK.

The Sideguard (Cappella Medical Devices Ltd, Galway, Ireland) was a self expanding stent designed to flare in a trumpet shape at the ostium of the side branch, with the aim to achieve full coverage of the side branch ostium. The device was relatively straightforward to use with application to the SB first after lesion preparation and then MV routine DES. However, the properties of this nitinol self-expanding device and lack of drug delivery resulted in case reports of MV migration and in my own experience of 10 cases within the UK Cappella registry we found TLR in 4 patients prompting early discontinuation. The product is no longer available.

**Current guidelines for bifurcation stenting**

The European Bifurcation Club (EBC) has the following expert consensus recommendations:

1. The Medina classification should be used in description of bifurcation lesions
2. A PS approach is recommended for most bifurcation lesions, however for complex lesions where the SB is large and supplies a significant coronary territory, a 2-stent approach may be used
3. POT should be used routinely for all bifurcation lesions
4. If a 2-stent approach is used, lesion preparation should be performed in MV and SB first and FKB and POT are mandatory
5. There should be a low threshold for use of intracoronary imaging (IVUS or OCT).

**Summary**

Bifurcation lesions are common and associated with increased risks of re-stenosis. While a provisional stent approach may be suitable in many cases, an upfront 2-stent approach should be considered in patients with complex anatomy or a large myocardial area supplied by the side branch. In this case, choice of bifurcation technique should be determined by the specific anatomy and operator experience. It is therefore important that PCI operators remain competent in 2-stent techniques.

**Declaration of conflicting interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) received no financial support for the research, authorship, and/or publication of this article.
**Ethical approval**
None.

**Guarantor**
CER is the guarantor for the manuscript.

**Contributorship**
CER and PDO prepared the manuscript.

**ORCID iD**
Claire E Raphael [https://orcid.org/0000-0002-2206-0413](https://orcid.org/0000-0002-2206-0413)

**References**

1. Serruys PW, Onuma Y, Garg S, et al. 5-year clinical outcomes of the ARTS II (arterial revascularization therapy study II) of the sirolimus-eluting stent in the treatment of patients with multivessel de novo coronary artery lesions. *J Am Coll Cardiol* 2010; 55: 1093–1101.

2. Ali ZA, Nef H, Escaned J, et al. Pathological findings at bifurcation lesions: the impact of flow distribution on atherosclerosis and arterial healing after stent implantation. *J Am Coll Cardiol* 2010; 55: 1679–1687.

3. Melikian N, Airoldi F and Di Mario C. Coronary bifurcation stenting. Current techniques, outcome and possible future developments. *Minerva Cardioangiol* 2004; 52: 365–378.

4. Ludwig J, Mohamed M and Mamas MA. Left main coronary bifurcations: Medina reclassification revisited as easy as ABC. *Catheter Cardiovasc Interv* 2021; 97: 186–187.

5. Chen S-L, Sheiban I, Xu B, et al. Impact of the complexity of bifurcation lesions treated with drug-eluting stents: the DEFINITION study (definitions and impact of complex bifurcation lesions on clinical outcomes after percutaneous coronary intervention using drug-eluting stents). *JACC Cardiovasc Interv* 2014; 7: 1266–1276.

6. Zhang J-J, Ye F, Xu K, et al. Multicentre, randomized comparison of two-stent and provisional stenting techniques in patients with complex coronary bifurcation lesions: the DEFINITION II trial. *Eur Heart J* 2020; 41: 2523–2536.

7. Finet G, Gilard M, Perrenot B, et al. Fractal geometry of arterial coronary bifurcations: a quantitative coronary angiography and intravascular ultrasound analysis. *EuroIntervention* 2008; 3: 490–498.

8. Mohamed MO, Polad J, Hildick-Smith D, et al. Impact of coronary lesion complexity in percutaneous coronary intervention: one-year outcomes from the large, multicentre €-Ultimaster registry. *EuroIntervention* 2020; 16: 603–612.

9. Ng J, Foin N, Ang HY, et al. Over-expansion capacity and stent design model: an update with contemporary DES platforms. *Int J Cardiol* 2016; 221: 171–179.

10. Banning AP, Lassen JF, Burzotta F, et al. Percutaneous coronary intervention for obstructive bifurcation lesions: the 14th consensus document from the European bifurcation club. *EuroIntervention* 2019; 15: 90–98.

11. Ali ZA, Nef H, Escaned J, et al. Safety and effectiveness of coronary intravascular lithotripsy for treatment of severely calcified coronary stenoses: the disrupt CAD II study. *Circ Cardiovasc Interv* 2019; 12: e008434.

12. Di Mario C, Iakovou I, van der Giessen WJ, et al. Optical coherence tomography for guidance in bifurcation lesion treatment. *EuroIntervention* 2010; 6 Suppl J: J99–J106.

13. Holm NR, Andreasen LN, Walsh S, et al. Rational and design of the European randomized optical coherence tomography optimized bifurcation event reduction trial (OCTOBER). *Am Heart J* 2018; 205: 97–109.

14. Finet G, Derimay F, Motreff P, et al. Comparative analysis of sequential proximal optimizing technique versus kissing balloon inflation technique in provisional bifurcation stenting. *JACC Cardiovasc Interv* 2015; 8: 1308–1317.

15. Chen SL, Zhang JJ, Ye F, et al. Study comparing the double kissing (DK) crush with classical crush for the treatment of coronary bifurcation lesions: the DKCRUSH-I bifurcation study with drug-eluting stents. *Eur J Clin Invest* 2008; 38: 361–371.

16. Chen S-L, Zhang J-J, Han Y, et al. Double kissing crush versus provisional stenting for left main distal bifurcation lesions. *J Am Coll Cardiol* 2017; 70: 2605–2617.

17. Chen S-L, Xu B, Han Y-L, et al. Clinical outcome after DK crush versus culotte stenting of distal left main bifurcation lesions. *JACC Cardiovasc Interv* 2015; 8: 1335–1342.

18. Stone GW, Sabik JF, Serruys PW, et al. Everolimus-eluting stents or bypass surgery for left main coronary artery disease. *N Engl J Med* 2016; 375: 2223–2235.

19. Mäkikallio T, Holm NR, Lindsay M, et al. Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial. *Lancet (London, England)* 2016; 388: 2743–2752.

20. Taggart D and Gaudino M. PCI or CABG for left main coronary artery disease. *N Engl J Med* 2020; 383: 290–294.

21. Pagano D. Changing evidence, changing practice, www.eacts.org/changing-evidence-changing-practice/ (accessed 17 October 2020).

22. Modolo R, Chichareon P, van Klaveren D, et al. Impact of non-respect of SYNTAX score II recommendation for surgery in patients with left main coronary artery disease treated by percutaneous coronary intervention: an EXCEL substudy. *Eur J Cardiothorac Surg* 2020; 57: 676–683.

23. Windecker S, Kolh P, Alfonso F, et al.; Authors/Task Force members. ESC/EACTS guidelines on myocardial revascularization. *Eur Heart J* 2014; 35: 2541–2619.

24. Kandzari DE, Gershlick AH, Serruys PW, et al. Outcomes among patients undergoing distal left main percutaneous coronary intervention. *Circ Cardiovasc Interv* 2018; 11: e007007.

25. Buysschaert I, Dubois CL, Dens J, et al. Three-year clinical results of the Axxess Biolimus A9 eluting bifurcation
stent system: the DIVERGE study. *EuroIntervention* 2013; 9: 573–581.

26. Généreux P, Kumsars I, Lesiak M, et al. A randomized trial of a dedicated bifurcation stent versus provisional stenting in the treatment of coronary bifurcation lesions. *J Am Coll Cardiol* 2015; 65: 533–543.

27. Fath-Ordoubadi F, Hauptmann K-E, Latib A, et al. TCT-690 safety and clinical efficacy of Sideguard® stent for treatment of bifurcation lesions: Interim results from the European Sideguard® bifurcation registry study. *J Am Coll Cardiol* 2012; 60: B201.

28. Steigen TK, Maeng M, Wiseth R, et al.; Nordic PCI Study Group. Randomized study on simple versus complex stenting of coronary artery bifurcation lesions. *Circulation* 2006; 114: 1955–1961.

29. Ferenc M, Gick M, Kienzle R-P, et al. Randomized trial on routine vs. provisional T-stenting in the treatment of de novo coronary bifurcation lesions. *Eur Heart J* 2008; 29: 2859–2867.

30. Colombo A, Bramucci E, Saccà S, et al. Randomized study of the crush technique versus provisional side-branch stenting in true coronary bifurcations. *Circulation* 2009; 119: 71–78.

31. Behan MW, Holm NR, de Belder AJ, et al. Coronary bifurcation lesions treated with simple or complex stenting: 5-year survival from patient-level pooled analysis of the Nordic bifurcation study and the British bifurcation coronary study. *Eur Heart J* 2016; 37: 1923–1928.

32. Chen S-L, Santos T, Zhang J-J, et al. A randomized clinical study comparing double kissing crush with provisional stenting for treatment of coronary bifurcation lesions: results from the DKCRUSH-II (double kissing crush versus provisional stenting technique for treatment of coronary bifurcation lesions) trial. *J Am Coll Cardiol* 2011; 57: 914–920.

33. Niemelä M, Kervinen K, Erglis A, Nordic-Baltic PCI Study Group, et al. Randomized comparison of final kissing balloon dilatation versus no final kissing balloon dilatation in patients with coronary bifurcation lesions treated with main vessel stenting: the Nordic-Baltic bifurcation study III. *Circulation* 2011; 123: 79–86.

34. Chen S-L, Ye F, Zhang J-J, et al. Randomized comparison of FFR-guided and angiography-guided provisional stenting of true coronary bifurcation lesions. *JACC Cardiovasc Interv* 2015; 8: 536–546.

35. Erglis A, Kumsars I, Niemelä M, Nordic PCI Study Group, et al. Randomized comparison of coronary bifurcation stenting with the crush versus the culotte technique using sirolimus eluting stents. *Circ Cardiovasc Interv* 2009; 2: 27–34.

36. Hildick-Smith D, Behan MW, Lassen JF, et al. The EBC TWO study (European bifurcation coronary TWO). *Circ Cardiovasc Interv* 2016; 9.e003643.DOI: 10.1161/CIRCINTERVENTIONS.115.003643.

37. Walsh SJ, Hanratty CG, Watkins S, et al. Culotte stenting for coronary bifurcation lesions with 2nd and 3rd generation everolimus-eluting stents: the CELTIC bifurcation study. *EuroIntervention* 2018; 14: e318–e324.